A Phase II Trial of Flavopiridol in Patients With Metastatic Androgen Independent Prostate Cancer
I. Evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen
independent adenocarcinoma of the prostate.
II. Assess the toxic effects of flavopiridol in this patient population.
Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4
courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects
may receive a dose escalation. Patients are followed every 3 months until death.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
George Wilding, MD
University of Wisconsin, Madison
United States: Food and Drug Administration
|Beckman Research Institute, City of Hope||Los Angeles, California 91010|
|University of Wisconsin Comprehensive Cancer Center||Madison, Wisconsin 53792|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|University of California Davis Cancer Center||Sacramento, California 95817|